Constitutive opioid receptor activation: A prerequisite mechanism involved in acute opioid withdrawal

Addiction Biology

Volumn 10, Issue 2, 2005, Pages 131-137

  Freye, Enno ^a,c   Levy, J V ^b  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF THE PACIFIC   (United States)

^c NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; NALTREXONE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SUFENTANIL;

AMPLITUDE MODULATION; ARTICLE; BLOOD PRESSURE; COLON DILATATION; CONTROLLED STUDY; DETOXIFICATION; DOG; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; EVOKED SOMATOSENSORY RESPONSE; GNAWING; HEART RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; MYDRIASIS; OPIATE ADDICTION; PRECIPITATION; PRIORITY JOURNAL; RHINORRHEA; SALIVATION; SYMPTOMATOLOGY; YAWNING;

ACUTE DISEASE; ANIMALS; BIOTRANSFORMATION; DOGS; EVOKED POTENTIALS, SOMATOSENSORY; NALTREXONE; NARCOTICS; PROTEIN KINASE C; RECEPTORS, OPIOID; SOMATOFORM DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; SUFENTANIL;

EID: 22144443151     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556210500123019     Document Type: Article

References (68)

1. Ammon-Treiber S, Höllt V. Morphine-induced changes of gene expression in the brain. Addict Biol 2005;10:81-91.
2. Arden JR, Segredo V, Wang Z, Lameh J, Sadee W. Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 1995;65:1636-45.
3. Basbaum AI. Insights into the development of opioid tolerance. Pain 1995;61:349-52.
4. 2 (CTAP) and the protein kinase inhibitor H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 1996;277:484-90.
5. Blumberg H, Dayton HB Naloxone, naltrexone, and related noroxymorphones. In: Braude MC, Harris LS, Smith MJP, Villareal JE, editors. Narcotic antagonists, vol 8. New York: Raven; 1974, pp. 33-43.
6. Boulard G, Maurette P, Pouget P et al. Withdrawal syndrome after stopping fentanyl sedation in neurological intensive care. Ann Fr Anesth Reanim 1983;2:100-1.
7. Buchsbaum MS, Davis GC, Bunney WE Jr. Naloxone alters pain perception and somatosensory evoked potentials in normal subjects. Nature 1977;270:620-2.
8. Buchsbaum MS, Davis GC, Naber D, Pickar D. Pain enhances naloxone-induced hyperalgesia in humans as assessed by somatosensory-evoked potentials. Psychopharmacology 1983;79:99-103.
9. Butler SH, Colpitts YH, Gagliardi GJ, Chen AC, Chapman CR. Opiate analgesia and its antagonism in dental event-related potentials: evidence for placebo antagonism. Psychopharmacology 1983;79:325-8.
10. Cami J, Farré M. Drug addiction. N Engl J Med 2003;349:975-86.
11. Carlezon WA Jr, Nestler EJ. Elevated levels of GluR1 in the midbrain: trigger for sensitization to drugs of abuse? Trends Neurosci 2002;25:610-15.
12. Chapmann CR, Chen CAN, Harkins SW. Brain evoked potentials as correlates of laboratory pain: A review and perspective. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG, editors. Advances in pain research and therapy, vol 3. New York: Raven Press; 1979, pp. 791-803.
13. Cooper DMF, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature 1995;374:421-4.
14. Cox BM. Molecular and cellular mechanisms in opioid tolerance. In: Basbaum AI, Besson JM, editors. Towards a new pharmacotherapy of pain. New York: John Wiley & Sons; 1991, pp. 137.
15. Dashwood MR, Debnam ES, Bagnall J, Thompson CS. Autoradiographic localisation of opiate receptors in rat small intestine. Eur J Pharmacol 1985;107:267-9.
16. Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend 2002;65:283-90.
17. Flacke JW, Flacke WE, Williams GD. Acute pulmonary edema following naloxone reversal of high dose morphine anesthesia. Anesthesiology 1977;47:376-8.
18. Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003;8:211-17.
19. Freye E, Buhl R, Schenk GK. Somatosensory-evoked potentials (SEPs) are effected differently by mu- and kappa-selective opioids in the dog. Funct Neurol 1987;2:281-92.
20. Freye E, Buhl R. Somatosensory-evoked potentials for the evaluation of analgesic properties of nalbuphine in man. Anesth Analg 1986;65:551.
21. Freye E, Hartung E. Naloxone induces excitation of the cardiovascular system and a rise in myocardial oxygen consumption in fentanyl and meperidine-anesthetized dogs. Acta Anaesth Belg 1982;33:89-97.
22. R): a case study. Eur J Pain 2000;4:307-11.
23. Freye E, Levy JV, Partecke L. Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD) - correlation with neurophysiological parameters. Neurophysiol Clin 2004;34:81-9.
24. Freye E, Neruda B, Smith OW. Studies on the abstinence-like overshoot following reversal of the potent 19-isoamyl derivative of etorphine with naloxone. A comparison with the opioids fentanyl and alfentanil. Arzneimittelforschung 1997;47:6-9.
25. Freye E, Schmidhammer H, Latasch L. 14-Methoxymetopon, a potent opioid, induces no respiratory depression, less sedation, and less bradycardia than sufentanil in the dog. Anesth Analg 2000;90:1359-64.
26. Gildenberg PL, Krishna Murthy KS, Adler MW, Frost EAM. The effect of morphine on evoked potentials in naive, tolerant and withdrawn rats. In: Kosterlitz HW, editor. Opiates and endogenous opioid peptides. Amsterdam: North-Holland Publishing Co.; 1976, pp. 247-56.
27. Gölz J, Partecke G. Katamnestische Entwicklung Opiatabhängiger nach Naltrexon-induziertem Entzug, naltrexongestützter Rü ckfallprophylaxe und ambulanter psychosozialer Nachsorge. Suchttherapie 2000;1:116-72.
28. Gucker S, Bidlack JM. Protein kinase C activation increases the rate and magnitude of agonist-induced d-opioid receptor down regulation in NG108-15 cells. Mol Pharmacol 1992;42:656-61.
29. Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase C. Biochemistry 1984;23:5036.
30. Jasinski DR, Mansky PA. Evaluation of nalbuphine for abuse potential. Clin Pharmacol Ther 1972;13:78-90.
31. Jasinski DR. Assessment of the abuse potentiality of morphine-like drugs. In: Martin WR, editor. Drug addiction, vol 1. Berlin: Springer; 1977, pp. 197-258.
32. Johnson PS, Wang JB, Wang WF, Uhl GR. Expressed mu opiate receptor couples to adenylate cyclase and phosphatidyl inositol turnover. Neuroreport 1994;5:507-9.
33. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750-5.
34. Kawamoto S, Hidaka H. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine (H-7) is a selective inhibitor of protein kinase C in rabbit platelets. Biochem Biophys Res Comm 1984;125:258-61.
35. Kochs E, Scharein E, Mollenberg O, Bromm B, Schulte am Esch J. Analgesic efficacy of low-dose ketamine. Somatosensory-evoked responses in relation to subjective pain ratings. Anesthesiology 1996;85:304-14.
36. Kolb L, Himmelsbach CK. Clinical studies of drug addiction. III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am J Psychiatry 1938;94:759-97.
37. Kosten TR, Morgan C, Kleber HD. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA Res Monogr 1992;121:101-19.
38. Law PY, McGinn TM, Wick MJ, Erikson LJ, Evans C, Loh HH. Analysis of delta opioid receptor activities stably expressed in CHO cells lines: function of receptor density? J Pharmacol Exp Ther 1994;271:1686-94.
39. Lewis JW, Walter D. Buprenorphine - background to its development as a treatment for opioid dependence. NIDA Res Monogr 1992;121:5-11.
40. 3H]-sulfentanil, a superior ligand for the mu-opiate receptor: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol 1983;87:209-25.
41. Loh HH, Smith AP. Molecular characterization of opioid receptors. Annu Rev Pharmacol Toxicol 1990;30:123-47.
42. Lohmann AB, Smith FL. Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups. Pediatr Res 2001;49:50-5.
43. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62:259-74.
44. Mayer DJ, Mao J, Price DD. The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain 1995;61:365-74.
45. Moore MP, Greene SA. A method for assessing noxious stimuli in anaesthetized dogs. In:van Poznak A, editor. Animal pain, short CE. London: Churchill Livingstone; 1979, pp. 439-46.
46. Narita M, Feng Y, Makimura M, Hoskins B, Ho IK. A protein kinase inhibitor H-7, inhibits the development of tolerance to opioid antinociception. Eur J Pharmacol 1994;271:543-5.
47. Narita M, Makimura M, Feng Y, Hoskins B, Ho IK. Influence of chronic morphine treatment on proteine kinase C activity: comparison with butorphanol and implication for opioid tolerance. Brain Res 1994;650:175-9.
48. Ness TJ, Metcalf AM, Gebhart GF. A psychophysiological study in humans using phasic colonic distension as a noxious visceral stimulus. Pain 1990;43:377-86.
49. Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neuronal plasticity. Neuron 1993;11:995-1006.
50. Nestler EJ. Molecular neurobiology of addiction. Am J Addict 2001;10:201-17.
51. Niemegeers CJ, Schellekens KH, Van Bever WF, Janssen PA. Sufentanil, a very potent and extremely safe intravenous morphine-like compound in mice, rats and dogs. Arzneimittelforschung 1976;26:1551-6.
52. North R. Opiates, opioid peptides and single neurones. Life Sci 1979;24:1527-45.
53. Paronis CA, Holtzman SG. Development of tolerance to the analgesic activity of mu agonists after continuous infusion of morphine, meperidine or fentanyl in rats. J Pharmacol Exp Ther 1992;262:1-9.
54. Petry NM, Bickel WK, Badger GJ. A comparsion of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible? Addiction 2000;95:1069-77.
55. Saitoh M, Naka M, Hidaka H. The modulatory role of myosin light chain phosphorylation in human platelet activation. Biochem Biophys Res Commun 1986;140:280-7.
56. Smith FL, Javed R, Elzey MJ et al. Prolonged reversal of morphine tolerance with no reversal of dependence by protein kinase C inhibitors. Brain Res 2002;958:28-35.
57. Smith TC. Comparison of naloxone and naltrexone in man. Anesthesiology 1979;51:S573.
58. Sosnowski M, Yaksh TL. Differential cross-tolerance between intrathecal morphine and sufentanil in the rat. Anesthesiology 1990;73:1141-7.
59. Stevens CW, Yaksh TL. Time course characteristics of tolerance development to continuously infused antinociceptive agents in rat spinal cord. J Pharmacol Exp Ther 1989;251:216-23.
60. Sweitzer SM, Wong SM, Tjolsen A, Allen CP, Mochly-Rosen D, Kendig JJ. Exaggerated nociceptive responses on morphine withdrawal: roles of protein kinase C e and g. Pain 2004;110:281-9.
61. Tokuyama S, Ho IK, Yamamoto T. A protein kinase inhibitor, H-7, blocks naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats. Brain Res Bull 2000;52:363-9.
62. Vanderah TW, Ossipov MH, Lai J, Malan TP Jr, Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending fascilitation and spinal dynorphin. Pain 2001;92:5-9.
63. Verebey K, Volavka J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;20:315-28.
64. Villarreal JE, Seevers MH. Evaluation of new compounds for morphine-like physical dependence in the rhesus monkey. 30th CPPD Meeting, Indianapolis, IN, 1968.
65. Wang Z, Bilsky EJ, Porreca F, Sadee W. Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 1994;54:339-50.
66. Wauquier A. Neurophysiologische Untersuchungen mit dem kurzwirksamen, intravenösen Analgetikum Alfentanil. In: Doenicke A, editor. Alfentanil. Berlin: Springer; 1982, pp. 78-89.
67. Wiley JN, Downs DA. Lack of antagonism by naloxone of the analgesic and locomotor stimulant actions of ketamine. Life Sci 1982;31:1071-5.
68. Xie GX, Meng F, Mansour A et al. Primary stucture and functional expression of a guinea pig kappa opioid (dynorphin) receptor. Proc Natl Acad Sci USA 1994;91:3779-83.